美国折点更新:2022年ASM临床微生物学开放会议摘要
该文综述美国抗菌药物敏感性试验折点设定流程,指出调查显示高达70%的美国CAP认证实验室和45%的美国以外CAP认证实验室使用过时折点。CAP已实施检查表要求确保使用最新折点,2022年6月ASM CMO会议讨论了缩小折点修订与实施差距的解决方案,包括明确数据要求、仅报告MIC以获监管许可、生成临床数据、倡导、教育及加强利益相关方对话。
要点
- 美国高达70%的CAP认证实验室使用过时折点解读药敏结果。
- CAP已实施检查表要求确保CAP认证实验室使用最新临床折点。
- 解决方案包括明确数据要求、仅报告MIC、生成临床数据、倡导、教育及加强对话。
核心结论
- 过时折点的持续使用是多因素问题,需实验室、制造商、标准组织和监管机构协作解决。
- CAP已实施检查表要求,2022年ASM CMO会议提出了缩小折点修订与实施差距的多种解决方案。
研究设计与样本
- 本文为迷你综述,总结了美国折点设定流程,并基于调查和2022年6月ASM临床微生物学开放会议讨论提出解决方案。
- 调查显示高达70%的美国CAP认证实验室和45%的美国以外CAP认证实验室使用过时临床折点。
主要发现
- 过时折点使用的原因是多方面的,涉及实验室、商业AST设备制造商、标准制定组织和监管机构遇到的障碍。
- CAP已实施检查表要求,以确保CAP认证实验室使用最新临床折点。
关键数值与推荐
- CAP认证实验室需满足检查表要求以使用最新临床折点。
- 会议讨论的解决方案包括明确数据要求和仅报告MIC用于AST设备的监管许可。
临床怎么用
- CAP认证实验室应遵循检查表要求,确保使用最新临床折点解读药敏结果。
- 利益相关方应协作推进折点更新与实施,包括明确数据要求、仅报告MIC、生成临床数据、倡导、教育及加强对话。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate antimicrobial susceptibility testing (AST) and reporting are essential for guiding appropriate therapy for patients and direction for public health prevention and control actions. A critical feature of AST reporting is the interpretation of AST results using clinical breakpoints for reporting as susceptible, susceptible-dose dependent, intermediate, or resistant. Breakpoints are subject to continuous adjustment and updating to best reflect current clinical data. These breakpoint changes can benefit patients and public health only if adopted in a timely manner. A recent survey identified that up to 70% of College of American Pathologists (CAP)-accredited U.S. laboratories and 45% of CAP-accredited laboratories outside the U.S. use various obsolete clinical breakpoints to interpret AST results to guide patient care. The reason for the ongoing use of obsolete breakpoints is multifactorial, including barriers encountered by laboratories, commercial AST device manufacturers, standards development organizations, and regulatory bodies alike. To begin to address this important patient safety issue, CAP implemented checklist requirements for CAP-accredited laboratories to ensure up-to-date clinical breakpoint use. Furthermore, the topic was discussed at the June 2022 American Society for Microbiology Clinical Microbiology Open (CMO) with various stakeholders to identify potential solutions. This minireview summarizes the breakpoint setting process in the U.S. and highlights solutions to close the gap between breakpoint revisions and implementation in clinical and public health laboratories. Solutions discussed include clarification of data requirements and minimum inhibitory concentration only reporting for regulatory clearance of AST devices, clinical data generation to close breakpoints gaps, advocacy, education, and greater dialogue between stakeholders.
引用
- Patel JB, Alby K, Humphries R, et al. Updating breakpoints in the United States: a summary from the ASM Clinical Microbiology Open 2022. J Clin Microbiol. 2023. PMID: 37791777. doi:10.1128/jcm.01154-22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。